Thermosome

Our proprietary drug development activities focus on cancer patients with locally advanced solid tumors. Improve antitumor behavior in neoadjuvant treatment concepts or enable long-term application for non-resectable tumors.

It is our goal to utilize our proprietary platform technology and know-how for the development of improved therapeutics that create significant value to patients. Our technology platform is tailored for treating localized diseases in which the activity of traditional systemically administered drugs is limited due to insufficient drug delivery into the target tissue and/or effective dosing is hindered by systemic side effects.